ABS Investment Management’s Dianthus Therapeutics DNTH Stock Holding History

ABS Investment Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$195K	Buy	+97	New	+$8.47K	0.12%	95

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

ABS Investment Management's DNTH Position: Q2 2026 in Review

ABS Investment Management opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 97 shares worth $195K. The stake represents 0.12% of the portfolio and ranks #95 among its holdings.

244 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

ABS Investment Management held 97 shares of Dianthus Therapeutics worth $195K as of Q2 2026.
Dianthus Therapeutics was a new ABS Investment Management position in Q2 2026.
Dianthus Therapeutics made up 0.12% of ABS Investment Management's portfolio in Q2 2026, its #95 holding.
244 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on ABS Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.